Molecular Formula | C17H25NO7S |
Molar Mass | 387.45 |
Melting Point | 189-192°C (A)(lit.) |
Specific Rotation(α) | -0.6 º (per USP 25 ºC) |
Water Solubility | soluble |
Solubility | H2O: soluble2.5g/mL (stable for several days at 4°C.) |
Appearance | Powder |
Color | white |
Merck | 14,875 |
BRN | 6109275 |
Storage Condition | Poison room |
Sensitive | Light Sensitive |
Physical and Chemical Properties | Chemical properties colorless crystals or white crystalline powder. The melting point was 190-194 °c. 1g of the crystals were soluble in 0.4ml of water, 2.5ml of boiling alcohol chemical book, 5ml of alcohol, 2.5ml of glycerol, 420ml of chloroform, 3000mL of ether. Odorless, with weathering, easy to deteriorate in light. The taste was extremely bitter. Highly toxic. |
Use | Use of anticholinergic drugs, can relieve smooth muscle spasm, inhibit gland secretion. For gastric and duodenal ulcer, gastrointestinal tract, kidney, biliary colic, mydriatic examination and optometry, keratitis, Iris ciliary body inflammation and pre-anesthetic administration, also used for organophosphorus pesticide poisoning, infective Shock and antimony preparations caused by acute cardiogenic cerebral ischemia syndrome. |
In vitro study | Tropine increases the release of the neurotransmitter dopamine into the vitreous (250 mg) in vitro (100-500 mM) and in vivo. Tropine induces spreading depression (SD) in the cerebral cortex in vitro. Atropine reduces the ERG B and d-waves, leads to damped oscillations of the RPE potential, and reverses the ERG c wave. In the retina, Atropine inhibits myopia only at doses that produce severe non-specific side effects. |
In vivo study | Atropine(1.0 mg/kg, I. P.), but not methylatropine(1.0 mg/kg, I. P.), administration immediately after training mice prevented the enhancement of memory induced by both doses of anticholinesterase. In dogs, Atropine effectively prevents bradycardia and second-degree heart block, which leads to alternating pulses and hypertension. In rats, Atropine had no effect on treatment-induced acetylcholine output in the presence of 10 nM neostigmine, but caused larger and longer increases in the presence of 100 nM and 1000 nM neostigmine. Not only did Atropine block the CGS-induced increase in rapid eye movement (REM) sleep, but it also tended to decrease REM sleep compared to rats treated with Atropine prior to saline. Atropine reduced the fatigue time of normal rats by 67%, adrenodemultivated (ADM) by 96.2, and reduced the release of exercise-induced Pituitary prolactin by 50% and 90% in normal rats and ADM rats, respectively. |
Hazard Symbols | T+ - Very toxic |
Risk Codes | R26/28 - Very toxic by inhalation and if swallowed. R43 - May cause sensitization by skin contact R36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | S23 - Do not breathe vapour. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S1 - Keep locked up. S25 - Avoid contact with eyes. |
UN IDs | UN 1544 6.1/PG 2 |
WGK Germany | 2 |
RTECS | CK2455000 |
FLUKA BRAND F CODES | 3-8-10 |
TSCA | Yes |
HS Code | 29399900 |
Hazard Class | 6.1 |
Packing Group | II |
Zhang Lei , baiqingshan , Wang Liang
Abstract:
Objective: to establish the quality control standard for compound Belladonna oral solution. Methods: atropine sulfate, scopolamine and anisodamine were identified by RP-HPLC. The content of atropine sulfate was determined by RP-HPLC. The chromatographic conditions were as follows: silica gel bonded with eighteen alkyl silane as filler; Acetonitrile-phosphate buffer (pH 2.8)(10:90) as mobile phase; The detection wavelength was 210 nm; The flow rate was 1.0 mL.min-1; The injection volume was 20$L; The column temperature was 30. Results: the sample solution chromatogram showed the same chromatographic peaks of atropine sulfate, scopolamine and anisodamine as the reference solution chromatogram, and the resolution was good, the linear range of atropine sulfate was 15.29~152.9 $G. M. L-1 (r = 0.9996). The average recovery (n = 6) was 100.2% with RSD of 1.7%. Conclusion: The method is accurate, reliable and specific, which provides the basis for the establishment of the quality standard of compound Belladonna oral solution.expand
Key words:
compound Belladonna oral solution atropine sulfate scopolamine anisodamine HPLC
DOI:
CNKI:SUN:YWFX.0.2013-08-029
cited:
year:
2013
utility model
Application (patent) number:
CN202021281609.8
application date:
20200702
Public/Announcement Number:
CN212832770U
Public/announcement date:
20210330
applicant (patent):
Hubei Xinghua Pharmaceutical Co., Ltd.
inventor:
National and provincial code:
CN420115
Abstract:
The utility model discloses A filling device for Atropine Sulfate Injection production, which relates to the technical field of Atropine Sulfate Injection production, and comprises an operation box and A threaded rod A, the right side of the operation box is provided with A rectangular groove, and one end of the threaded rod A is rotatably connected to the side of the baffle, and the threaded rod A is threaded to the placement plate, and the lower surface of the placement plate is in contact with the upper surface of the support plate, the other end of the threaded rod A runs through the left side wall of the operation box and is fixedly connected to the output end of the motor through A coupling. The motor is mounted on the upper surface of the mounting plate, and the mounting plate is fixedly connected to the side of the operation box, and the upper surface of the placement plate is provided with a plurality of equidistant distribution of round grooves, and a filling machine is installed in the operation box, and the upper surface of the placement plate is fixedly connected with a clamping mechanism, the utility model can prevent the bottle from shaking in the process of moving and make
Sun , Wu Xiaoming , Gao Peiping , Liang Xiaoyan , Xiao Jianhua
Abstract:
objective: to observe the changes of active ingredients of atropine sulfate eye drops in different environments, and to predict the validity of the preparation. Methods: The content of atropine sulfate eye drops was determined by HPLC. The preparation was investigated under different acidity environment, light acceleration test, constant temperature acceleration test and sample observation test. Results: the optimum pH of the preparation was 3.5~5.5, and it was sensitive to light. The validity period of the preparation was 13 months at room temperature. Conclusion: the preparation is stable under acidic condition and should be stored in the dark.
Key words:
atropine sulfate formulation stability validity period
DOI:
CNKI:SUN:ZGYZ.0.2008-10-044
cited:
year:
2008